Rapid modifications of N-substitution in iminosugars: Development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease-Reference-Cited by-同舟云学术

Rapid modifications of N-substitution in iminosugars: Development of new β-glucocerebrosidase inhibitors and pharmacological chaperones for Gaucher disease

Published:2013-09 Issue:17 Volume:21 Page:5021-5028
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Cheng Wei-Chieh,Weng Chen-Yi,Yun Wen-Yi,Chang Shang-Yu,Lin Yu-Chun,Tsai Fuu-Jen,Huang Fu-Yung,Chen Yun-Ru

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference45 articles.

1. Principles of lysosomal membrane degradation

2. Phenotype, diagnosis, and treatment of Gaucher's disease

3. Common and Uncommon Pathogenic Cascades in Lysosomal Storage Diseases

4. ER retention and degradation as the molecular basis underlying Gaucher disease heterogeneity

5. Pharmacological chaperone therapy for Gaucher disease: a patent review

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multivalent pyrrolidines acting as pharmacological chaperones against Gaucher disease;Bioorganic Chemistry;2024-05

2. Discovery of small-molecule protein stabilizers toward exogenous alpha-l-iduronidase to reduce the accumulated heparan sulfate in mucopolysaccharidosis type I cells;European Journal of Medicinal Chemistry;2023-02

3. Harnessing polyhydroxylated pyrrolidines as a stabilizer of acid alpha-glucosidase (GAA) to enhance the efficacy of enzyme replacement therapy in Pompe disease;Bioorganic & Medicinal Chemistry;2023-01

4. First Example of Multivalent Pyrrolidines Acting as Pharmacological Chaperones Against Gaucher Disease;2023

5. Discovery of Small-Molecule Protein Stabilizers Toward Exogenous Alpha-L-Iduronidase to Reduce the Accumulated Heparan Sulfate in Mucopolysaccharidosis Type I Cells;SSRN Electronic Journal;2022